Lung cancer is a malignant tumor with the highest mortality in the world. The most common pathological type of lung cancer is non-small cell lung cancer (NSCLC). In recent years, immunotherapy has brought about epoch-making changes in the treatment of NSCLC. In particular, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have been approved for first-line and second-line treatment in patients with metastatic NSCLC. However, only 15% to 30% of patients with advanced NSCLC can achieve sustained remission and long-term survival from immunotherapy. Therefore, biomarker for predicting the efficacy of immunotherapy is particularly important. This article reviews the relevant literatures on predictive biomarkers for immunotherapy of NSCLC and provides direction for future research. .
【中文题目：非小细胞肺癌免疫治疗生物标志物的 研究进展】 【中文摘要：肺癌是全球死亡率最高的恶性肿瘤，非小细胞肺癌（non-small cell lung cancer, NSCLC）是其最常见的病理类型。近年来，免疫治疗给NSCLC的治疗带来划时代的变革，尤其是针对程序性死亡受体1（programmed cell death 1, PD-1）/程序性死亡配体1（programmed cell death ligand 1, PD-L1）的免疫检查点抑制剂（immune checkpoint inhibitors, ICIs），目前已被批准用于转移性NSCLC或部分局部晚期NSCLC患者的一线治疗和二线治疗。然而，仅15%-30%晚期NSCLC患者可以从免疫治疗中获得持续缓解和长期生存，如何探寻良好的生物标志物来有效地预测免疫治疗的疗效是当前面临的巨大挑战之一。本文对NSCLC免疫治疗疗效预测生物标志物的研究进展进行综述。 】 【中文关键词：肺肿瘤；免疫治疗；生物标志物】.
Keywords: Biomarker; Immunotherapy; Lung neoplasms.